Lung Cancer Organoids and Patient Derived Tumor Xenografts

Launched by MAASTRICHT RADIATION ONCOLOGY · Oct 11, 2021

Keywords

ClinConnect Summary

This clinical trial is studying ways to better understand and treat lung cancer by creating models of the disease from patients' own tissues. When patients have surgery to remove lung cancer, extra tissue will be collected along with a small sample of blood. Researchers will use this material to develop "organoids," which are tiny, lab-grown versions of the patient’s lung cancer. These organoids will help scientists learn more about the cancer and test potential treatments.

To participate in this trial, you need to be someone who is scheduled to have surgery for lung cancer or is undergoing certain procedures like bronchoscopy, which allows doctors to look at the lungs in detail. There are no specific exclusions based on health conditions, so most patients with suspected lung cancer may be eligible. If you join the study, you can expect to provide some extra tissue and blood samples during your routine medical procedures, which could contribute to important research that benefits future lung cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients selected to undergo primary surgical resection of a primary lung cancer. All types of resection are eligible, e.g. wedge resection, segmental resection, lobectomy, pneumonectomy.
• • All patients with (suspected) lung cancer that will undergo a bronchoscopy or endobronchial ultrasound guided transbronchial needle aspiration (EBUS/EUS-TBNA) bronchoscopy.
• Exclusion Criteria:
• • There are no exclusion criteria